FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

Study authors measured savings, conversions to biosimilars, and payer policies for 3 originator brands Using commercial and public payer data, investigators observed that payer utilization management ...

Bevacizumab-bvzr…pegfilgrastim-bmez…infliximab-axxq…. Have you ever wondered what is behind the seemingly random letter strings attached to the nonproprietary names (also known as “proper names”) of ...

The FDA approved Celltrion USA’s Zymfentra (infliximab-dyyb), the world’s first and only subcutaneous infliximab product. Zymfentra is approved as a novel drug, and its development is based on ...

The FDA approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference Stelara (ustekinumab). The biosimilar was also approved with an interchangeability designation. The FDA ...

Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...